Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JUNO THERAPEUTICS INC

SummaryNewsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders

01/23/2018 | 09:11am EDT

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Juno Therapeutics, Inc. (“Juno Therapeutics” or the “Company”) (NASDAQ:JUNO) stock prior to January 22, 2018.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Juno Therapeutics to Celgene Corporation (NASDAGS: CELG) for $87 per share. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/juno-therapeutics-inc

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Juno Therapeutics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Celgene Corporation is underpaying for Juno Therapeutics shares, thus unlawfully harming Juno Therapeutics shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2018
All news about JUNO THERAPEUTICS INC
2018Merits of any Takeda bid for Shire questioned, shares slide
RE
2018Merits of any Takeda bid for Shire questioned, shares slide
RE
2018Drugmaker Shire soars as Japan's Takeda considers bid
RE
2018Sangamo in $3 billion gene-editing deal with Gilead
RE
2018JUNO THERAPEUTICS : Celgene Receives Antitrust Clearance for Juno Acquisition
BU
2018Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
2018THE LAW OFFICES OF VINCENT WONG : Reminds Investors of an Investigation of Juno Therapeuti..
BU
2018THE LAW OFFICES OF VINCENT WONG : Notifies Investors of an Investigation of Juno Therapeut..
BU
2018WEISSLAW LLP : Investigates Juno Therapeutics Inc. Acquisition
PR
2018Rigrodsky & Long, P.A. Announces Investigation of Juno Therapeutics, Inc. Buyout
BU
More news
Analyst Recommendations on JUNO THERAPEUTICS INC
More recommendations
Managers and Directors
Mark J. Gilbert Chief Medical Officer & Senior Vice President
Ann L. Lee Executive Vice President-Technical Operations
Mark J. Alles Director
Peter N. Kellogg Director
Nicole Keith Investor Relations Contact
Sector and Competitors
1st jan.Capi. (M$)
JUNO THERAPEUTICS INC90.24%0
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610